Common use of Post-Effective Date Trade Secrets Clause in Contracts

Post-Effective Date Trade Secrets. Neither party shall have any obligation to disclose any trade secrets or proprietary information that it develops during the Sharing Period except (a) in the case of Broncus, to the extent such trade secret or proprietary information is required to be disclosed by Broncus pursuant to the provisions of Section 2.1(f); and (b) in the case of Asthmatx, to the extent such trade secret or proprietary information is required to be disclosed by Asthmatx pursuant to the provisions of Section 2.2(f).. ***** Certain portions of this exhibit have been omitted and confidential treatment has been requested for these omitted portions pursuant to an application for confidential treatment sent to the Securities and Exchange Commission.

Post-Effective Date Trade Secrets. Neither party shall have any obligation to disclose any trade secrets or proprietary information that it develops during the Sharing Period except (a) in the case of Broncus, to the extent such trade secret or proprietary information is required to be disclosed by Broncus pursuant to the provisions of Section 2.1(f); and (b) in the case of Asthmatx, to the extent such trade secret or proprietary information is required to be disclosed by Asthmatx pursuant to the provisions of Section 2.2(f).. *. **** Certain portions of this exhibit have been omitted and confidential treatment has been requested for these omitted portions pursuant to an application for confidential treatment sent to the Securities and Exchange Commission.

Post-Effective Date Trade Secrets. Neither party shall have any obligation to disclose any trade secrets or proprietary information that it develops during the Sharing Period except (a) in the case of Broncus, to the extent such trade secret or proprietary information is required to be disclosed by Broncus pursuant to the provisions of Section 2.1(f); and (b) in the case of Asthmatx, to the extent such trade secret or proprietary information is required to be disclosed by Asthmatx pursuant to the provisions of Section 2.2(f).. *. **** Certain Confidential portions of this exhibit have been omitted and confidential treatment has been requested for these omitted portions pursuant to an application for confidential treatment sent to the Securities and Exchange Commission.